clear. Trivial mechanisms such as sequence differences between transgenic and endogenous EPO cDNAs as well as vector particleinduced inflammation could be ruled out a priori. Furthermore, the fact that anemia sporadically arose in 2 different macaque species upon gene transfer using several rAAV serotypes in 2 ectopic expression sites (muscle or lung versus kidney) rather suggests an EPO-specific effect. Thus, the autoimmune anemia might be due to the ectopic expression site of the transgene or to supraphysiologic expression levels that could induce posttranslational modifications; yet it may also be contributed by vector spreading in the draining lymph nodes and subsequent EPO expression in professional APCs. In addition, there was no clear correlation between elevated EPO levels and anemia, suggesting that the events occur in a haplotype-dependent manner.
These results are extremely important, not only because they teach us that in vivo gene delivery is effective, but also because they stress that the direct translation to the clinic of preclinical data obtained in inbred rodent models is not straightforward. Although the laboratory mouse has been invaluable in the preclinical gene therapy era, it shows limitations. Autoimmune responses to gene transfer have never been reported in these small animal models, possibly because they have not been identified or exhaustively assessed. In contrast, more relevant information in safety, efficiency, and immunologic consequences of gene transfer can be expected from wild and large animals. Thus, as vectors have now become efficient enough to allow effective gene delivery, experiments in nonhuman primates are more practical than before, and their more extensive implementation in preclinical studies may be a prerequisite before going to the clinic. For personal use only. on August 18, 2017. by guest www.bloodjournal.org From the authors did observe loss of myeloid engraftment at 16 weeks. The explanation for the discrepant results appears to be the capacity of wild-type competitor cells to "rescue" the early transplant defect of SCLdeleted cells. Also in the current issue, Kunisato and colleagues (page 3336) used a retroviral HSC transduction strategy to overexpress SCL or to inhibit it with a dominant-negative (DN) SCL construct. Overexpression of SCL increased short-term contribution to the myeloid lineage, whereas DN-SCL enhanced the contribution to lymphoid lineages without affecting long-term HSC proliferation. This was confirmed using fetal thymic organ cultures where single-sorted DN-SCL cells generated high numbers of T-committed cells and low numbers of myeloid-committed cells. Some effects were seen on erythroid (increased immature cells) but not on megakaryocytic differentiation in animals with DN-SCL that underwent HSC transplantation. The discrepancy between this and most other studies that do not show enhancement of lymphopoiesis could be related to DN-SCL interfering with bHLH motif-containing transcription factors other than SCL. A direct comparison in a competitive repopulation assay of HSC differentiation with SCL knocked down by DN-SCL, or excised by cre/lox, would be informative. 
HEMATOPOIESIS

Clearance receptor controls death and differentiation
Fetal macrophages associate intimately with developing erythroid cells and thymocytes, removing discarded nuclei and apoptotic cells in fetal liver and thymus. 2 and in murine lung and brain. 3 It is not generally appreciated that resident macrophages perform poorly understood trophic functions during hemopoiesis in the adult as well as in the fetus. 4 Stromal macrophages in bone marrow, for example, express nonphagocytic adhesion molecules for erythroblasts and developing neutrophils, whilst avidly ingesting extraded erythrocyte nuclei and apoptotic leukocytes. Their potential ability to express and secrete factors that control hemopoietic cell growth and differentiation has not been sufficiently studied. It is not clear from the published studies whether macrophage development is also defective in PSR knockout mice, although diminished phagocytosis of apoptotic cells by existing macrophages is clearly evident. Conversely, macrophages can express death-inducing surface receptors and secretory products. The present study shows that excessive production of proinflammatory cytokines such as tumor necrosis factor ␣ (TNF-␣) is unlikely to contribute to the mortality of PSR-deficient mice.
An important question that is not fully addressed in the present paper is whether defective apoptosis accompanies diminished clearance and abnormal differentiation. Whilst the emphasis here is on hemopoiesis, other studies suggest the interactions between developing cells, apoptosis, and phagocyte removal are more widespread in tissues, although not universal. 3 Many plasma membrane receptors have now been shown to contribute to binding and ingestion of apoptotic cells by macrophages, although in cases such as scavenger receptor A deficiency, the resultant phenotype is less marked, with minimal impact, if any, on apoptosis and differentiation 5 but more on inflammation. The role of PSR in cell-cell interactions is of a special nature, which should teach us more about the linkage between death and differentiation on the one hand and clearance of apoptotic cells on the other.
-Siamon Gordon
Oxford University
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VAP-1: a new antiinflammatory target?
Polymorphonuclear leukocyte (PMN) migration through the endothelium to sites of
